Theresa and Fab,

As discussed following are 2 documents I mentioned for your consideration and application. So far 5 people, that I know, have tired it and have had very good results.

1) Linus Pauling Therapy for Heart Disease is at http://www.paulingtherapy.com/ and copiously describes a non toxic, cost effective Orthomolecular approach using vitamin C and amino acids Lysine and Proline.

16] According to the Pauling/Rath 1994 United States patent, the amino acid lysine (lysine analogs), along with vitamin C and other antioxidants (e.g. Co-Q10, vitamin E and vitamin A), can, in sufficient concentration, inhibit Lp(a) binding to exposed lysine residues. Proline residues are also exposed by lesions in blood vessels. Later experiments showed that proline as well as lysine, with vitamin C, other amino acids and antioxidants, in oral amounts well past what is needed for prevention, becomes a solvent by inhibiting the binding of Lp(a). A binding inhibitor augmented with vitamin C can stop and apparently even reverses some plaque formations. Pauling and Rath even have a second U. S. patent for using these binding inhibitors as solvents to melt atherosclerotic plaques from human organs during organ transplants. The organ is dipped in the Lp(a) Binding Inhibitor solution and the plaques melt away.

U. S. Patent # 5,278,189 is for the prevention and treatment of occlusive cardiovascular disease with vitamin C and substances that inhibit the binding of lipoprotein-(a). The full patent is available:

http://www.uspto.gov/patft/

If you prefer I can email it as a pdf file attachment to you.

Backing this up with Vitamin B6 is described in the attached Joe Hattersley
paper "Vitamin B6: The overlooked Key to preventing heart attacks"

ABSTRACT: Vitamin B6 (pyridoxine) opens the door to eliminating the 20th century's epidemic of heart attacks, cardiac arrests and strokes. Although shunned by the researchers who receive the bulk of heart disease research funding, it is creating excitement among a growing number of investigators.
In this article relevant bits of B6's history are presented to show how it can prevent heart attacks with almost no side effects from moderate amounts. This article will also integrate the effects of vitamin B6 deficiency with Mathias Rath and Linus Pauling's theory (blaming heart attacks on deficient vitamin C and excess Lp(a) and Bruce Lipton's histamine theory into a general theory of atherogenesis.

http://www.friendsoffreedom.org/documentview.php?file=
Vitamin_B6_The_overlooked_Key_to_preventing_heart_attacks.PDF

As usual any effective products such as amino acids which are very effective for many diseases and essentially non toxic (far less toxic than even salt) are banned illegally by Health Canada to protect their pharmaceutical friends! So you will have get them from the states - 250 (500 mg) tablets of lysine are available for approx $5 from US Walmart stores. The underground cost in Canada is over $50 courtesy of Health Canada.

Chris Gupta

See also:

Reduction of Lipoprotein(a) in Postmenopausal Women

As a general surgeon who is interested in the prevention of postmenopausal heart disease and in particular in the reduction of lipoprotein(a) [Lp(a)], I read with great interest the recent review by Dr Mosca1 regarding the role of HRT. Rapid progression of arteriographically determined coronary artery disease has been significantly more common in subjects with Lp(a) levels higher than 25 mg/dL.2 Approximately 33% of the population have elevated levels of Lp(a) (>25 mg/dL), a condition that is an independent risk factor for coronary artery disease.3, 4 The treatment currently recommended for postmenopausal women with Lp(a) levels higher than 25 mg/dL consists of a combination of HRT and niacin.4 The adverse effects of niacin use are flushing, headache, and liver dysfunction. I am a 53-year-old woman with a significantly elevated level of Lp(a) (27 mg/dL), but I found that I had to stop taking niacin primarily because of headaches. Thus, after a thorough review of the literature, I began to follow the advice of Linus Pauling. For individuals who have an Lp(a) level higher than 25 mg/dL and a family history of heart disease, the recommendation is to take 3 g/d of both ascorbic acid and L-lysine monohydrochloride.5 After 6 months of this regimen, with no adverse effects, my Lp(a) level decreased to 14 mg/dL, a reduction of 48%. The Lp(a) testing was done by the highly reliable Lawrence Berkeley National Laboratory/Berkeley HeartLab Department Technology Transfer program. The theory is that lysine is an Lp(a)-binding inhibitor and thus blocks the Lp(a) attachment to the arterial blood vessel wall and that ascorbic acid helps to repair the collagen injury to the blood vessel and acts as an antioxidant.5-7 Currently, pilot studies are being conducted on the Pauling therapy of elevated levels of Lp(a).

Kathie M. Dalessandri, MS, MD
Point Reyes Station, Calif

1. Mosca L. The role of hormone replacement therapy in the prevention of
postmenopausal heart disease. Arch Intern Med. 2000;60:2263-2272.

2. Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW. Rapid
angiographic progression of coronary artery disease in patients with
elevated lipoprotein(a). Circulation. 1995;91:948-950. MEDLINE

3. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a)
and coronary heart disease in men aged 55 years and younger: a prospective
study. JAMA. 1996;276:544-548. MEDLINE

4. Superko HR. Did grandma give you heart disease? the new battle against
coronary artery disease. Am J Cardiol. 1998;82:34Q-46Q. MEDLINE

5. Pauling L, Rath M. Solution to the puzzle of human cardiovascular disease: its primary cause is ascorbate deficiency leading to the deposition of lipoprotein(a) and fibrinogen/fibrin in the vascular wall. J Orthomol Med. 1992;6:125-133.

6. Rath M, Pauling L. Hypothesis: lipoprotein(a) is a surrogate for
ascorbate. Proc Natl Acad Sci U S A. 1990;87:6204-6207. MEDLINE

7. Pauling L. The Last Interview [videotape]. Lisle, Ill: Intellisoft
Multimedia Inc; 1994.

(Arch Intern Med. March 12, 2001;161:772-773,)

Reduction of Lipoprotein(a) in Postmenopausal Women
http://archinte.ama-assn.org/issues/v161n5/ffull/ilt0312-4.html